Utilities Registry – Center for Health Decision Science

Filter results using search terms, or by selecting one or more valuation, condition, or population.

Valuation

Population

Condition

Viewing 1 - 10 of 44 results

Title	Year(s) of data collection	Valuation Method	Country	Condition
Selection of autoimmune disease health state utilities (Schreiber S et al., J Crohns Colitis. 2023. doi:10.1093/ecco-jcc/jjad018)	2017 - 2018	EQ-5D	Argentina, Australia, Belgium, Bulgaria, Canada, Croatia, Czechia, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Ireland, Israel, Italy, Japan, Korea (Republic of), Malaysia, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Serbia, Singapore, Slovakia, South Africa, Spain, Sweden, Switzerland, Taiwan (Province of China), Ukraine, United Kingdom of Great Britain and Northern Ireland, United States of America	Ulcerative colitis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics An RCT for filgotinib in 786 adults with moderately to severely active UC
Title Selection of neurological disease health state utilities (Gebrehiwet P et al., J Med Econ. 2023. doi:10.1080/13696998.2023.2192588)	Year(s) of data collection 2017 - 2019	Valuation Method EQ-5D-5L	Country Australia, Canada, Ireland, Netherlands, Spain, United States of America	Condition Amyotrophic lateral sclerosis
DOI 10.7910/DVN/VJSSSX Author(s) Registry, Utilities Description Health state utilities for neurological disease conditions Sample Characteristics 456 participants with clinical trial data from FORTITUDE-ALS that evaluated reldesemtiv versus placebo in patients with ALS
Title Selection of oncology health state utilities (Yang M et al., Value Health. 2023. doi:10.1016/j.jval.2023.02.00)	Year(s) of data collection 2016 - 2021	Valuation Method EQ-5D-5L	Country Austria, Belgium, China, France, Germany, Israel, Italy, Japan, Korea (Republic of), Netherlands, Poland, Spain, Switzerland, Taiwan (Province of China), United States of America	Condition Lung cancer
DOI 10.7910/DVN/L4V2LU Author(s) Registry, Utilities Description Health state utilities for oncology conditions Sample Characteristics 273 patients with non-small cell lung cancer harboring MET exon 14 skipping treated with tepotinib
Title Selection of autoimmune disease health state utilities (Saccà F et al., J Neurol. 2023. doi:10.1007/s00415-022-11517-w)	Year(s) of data collection 2018 - 2020	Valuation Method EQ-5D-5L	Country Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 167 participants in phase 3 RCT of efgartigimod, ADAPT trial
Title Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)	Year(s) of data collection 2021	Valuation Method EQ-5D-5L, HUI3	Country Belgium, Canada, Denmark, France, Germany, Italy, Japan, Netherlands, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 9000 participants in the general population norms study that included adult patients with gMG randomly assigned to treatment with efgartigimod or conventional therapy
Title Selection of COVID-19 health state utilities (Rosa RG et al., Intensive Care Med. 2023. doi:10.1007/s00134-022-06953-1)	Year(s) of data collection 2020 - 2022	Valuation Method EQ-5D-3L	Country Brazil	Condition COVID-19
DOI 10.7910/DVN/MJ4J77 Author(s) Registry, Utilities Description Health state utilities for states related to COVID-19 Sample Characteristics 1156 adults post-hospitalization COVID-19 patients
Title Selection of mental health health state utilities (Adu MK et al., Brain Sci. 2023. doi:10.3390/brainsci13020293)	Year(s) of data collection 2020 - 2022	Valuation Method EQ-5D-5L	Country Canada	Condition Depression
DOI 10.7910/DVN/QNA5ZF Author(s) Registry, Utilities Description Health state utilities for mental health conditions Sample Characteristics 78 participants in the patient-centered randomized controlled pilot trial investigating combining repetitive transcranial magnetic stimulation with internet-delivered cognitive behavior therapy for the treatment of resistant depression
Title Selection of autoimmune disease health state utilities (Dewilde S et al., Adv Ther. 2023. doi:10.1007/s12325-023-02437-w)	Year(s) of data collection 2019 - 2022	Valuation Method EQ-5D-5L, HUI3	Country Canada, Denmark, France, Germany, Italy, Japan, Spain, United Kingdom of Great Britain and Northern Ireland, United States of America	Condition Myasthenia gravis
DOI 10.7910/DVN/XTLOGB Author(s) Registry, Utilities Description Health state utilities for autoimmune disease conditions Sample Characteristics 1299 participants (EQ-5D-5L) and 549 participants (HUI3) from MyRealWorld-MG study
Title Selection of general population health health state utilities (Xie S et al., Eur J Health Econ. 2023. doi:10.1007/s10198-023-01566-x)	Year(s) of data collection 2019	Valuation Method EQ-5D-5L, SF-6Dv2	Country China	Condition General population health
DOI 10.7910/DVN/OE5E2K Author(s) Registry, Utilities Description Health state utilities for general population health conditions Sample Characteristics 3320 participants from the Chinese general population
Title Selection of general population health health state utilities (Zhang W et al., Haemophilia. 2022. doi:10.1111/hae.14615)	Year(s) of data collection 2021	Valuation Method SF-6Dv2	Country China	Condition General population health, Haemophilia
DOI 10.7910/DVN/OE5E2K Author(s) Registry, Utilities Description Health state utilities for general population health conditions Sample Characteristics 206 age and gender matched sample of the general population with people with haemophilia

Next results →